Who are Raltegravir and truvada's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dolutegravir/Lamivudine, Switch to DTG + 3TC, Dolutegravir/Lamivudine as a single pill, Dolutegravir / Lamivudine Pill, Raltegravir; Abacavir/Lamivudine, Sofosbuvir, Ribavirin, and Stribild.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/raltegravir-and-truvada.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Raltegravir and truvada — Competitive Intelligence Brief

Raltegravir and truvada (Raltegravir and truvada) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Raltegravir and truvada (Raltegravir and truvada) — The University of Texas Health Science Center, Houston. This combination uses raltegravir to block HIV integrase and truvada (emtricitabine/tenofovir) to inhibit reverse transcriptase, together suppressing HIV replication through dual antiretroviral action.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Raltegravir and truvada TARGET	Raltegravir and truvada	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Switch to DTG + 3TC	Switch to DTG + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Dolutegravir/Lamivudine as a single pill	Dolutegravir/Lamivudine as a single pill	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Dolutegravir / Lamivudine Pill	Dolutegravir / Lamivudine Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Raltegravir; Abacavir/Lamivudine	Raltegravir; Abacavir/Lamivudine	Central Institute of Epidemiology, Moscow, Russia	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase; HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTI) class)

ViiV Healthcare · 2 drugs in this class
Denver Infectious Disease Consultants, PLLC · 1 drug in this class
Fundacion SEIMC-GESIDA · 1 drug in this class
Fundação Bahiana de Infectologia · 1 drug in this class
Charlotte-Paige Rolle, MD · 1 drug in this class
Saint Michael's Medical Center · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
Hospitales Universitarios Virgen del Rocío · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Raltegravir and truvada — Competitive Intelligence Brief. https://druglandscape.com/ci/raltegravir-and-truvada. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab